Literature DB >> 35227051

Novel Indole Derivative as the First P-glycoprotein Inhibitor from the Skin of Indian Toad (Bufo melanostictus)

Prasad Neerati1, Sangeethkumar Munigadapa1.   

Abstract

Objectives: To study the inhibitory effect of novel indole derivative (NID) from Indian toad skin (Bufo melanostictus) on permeability glycoprotein (P-gp). Materials and
Methods: Dried Indian toad skin was used to isolate NID with column chromatography, and its structure was elucidated by infrared spectra, 13C nuclear magnetic resonance (NMR), 1H NMR spectra, and liquid chromatography-mass spectrometry. Female Wistar rats were used to determine LD50, in vitro permeability studies were done with the intestinal sac method, and in vivo pharmacokinetic studies were carried out to prove the P-gp inhibition using the rat model.
Results: The NID has shown increased clear permeability Papp (x10-6 cm/sec) significantly (p<0.001) from 1.04±0.11 to 2.90±0.08 in ileum 1.44±0.14 to 3.92±0.13 in jejunum this in vitro results confirmed that P-gp inhibited, this was further confirmed by in vivo studies in in vivo studies observed increased oral bioavailability of digoxin (DIG) significantly in NID treated groups from 3.26±0.25 to 7.47±0.18 ng/mL, the volume of distribution decreased from 232.56±64.59 to 86.57±7.04 L/kg. Area under the curve increased from 37.89±1.13 to 64.62±0.70 ng/mL/hr. This demonstrates NID increased the oral bioavailability of DIG significantly.
Conclusion: Many compounds were isolated from the Indian toad skin. This NID was not reported earlier. Results demonstrate NID increased the oral bioavailability of DIG significantly. The isolated NID from Indian toad skin proved as a potent P-gp inhibitor in both in vitro and in vivo studies, and further studies are needed to develop as a possible new drug candidate.

Entities:  

Keywords:  Clear permeability; bioavailability; novel indole derivative; permeability glycoprotein

Year:  2022        PMID: 35227051      PMCID: PMC8892550          DOI: 10.4274/tjps.galenos.2021.47417

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  36 in total

1.  Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication.

Authors:  Xian-Bing Kong; Zu-Kui Yang; Li-Jian Liang; Jie-Fu Huang; Han-Liang Lin
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Animal venom studies: Current benefits and future developments.

Authors:  Yuri N Utkin
Journal:  World J Biol Chem       Date:  2015-05-26

Review 3.  P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.

Authors:  Caroline A Lee; Jack A Cook; Eric L Reyner; Dennis A Smith
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-05       Impact factor: 4.481

4.  Morphology of the exocrine glands of the frog skin.

Authors:  J W Mills; B E Prum
Journal:  Am J Anat       Date:  1984-09

Review 5.  Importance of P-glycoprotein for drug-drug interactions.

Authors:  Hartmut Glaeser
Journal:  Handb Exp Pharmacol       Date:  2011

6.  Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.

Authors:  Monica A Summers; J Layne Moore; James W McAuley
Journal:  Ann Pharmacother       Date:  2004-08-24       Impact factor: 3.154

7.  A toad more traveled: the heterogeneous invasion dynamics of cane toads in Australia.

Authors:  Mark C Urban; Ben L Phillips; David K Skelly; Richard Shine
Journal:  Am Nat       Date:  2008-03       Impact factor: 3.926

Review 8.  P-glycoprotein Inhibition for Optimal Drug Delivery.

Authors:  Md Lutful Amin
Journal:  Drug Target Insights       Date:  2013-08-19

Review 9.  Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents.

Authors:  Ji Qi; C K Tan; Saeed M Hashimi; Abu Hasanat Md Zulfiker; David Good; Ming Q Wei
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-06       Impact factor: 2.629

Review 10.  Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.

Authors:  Famida G Hoosain; Yahya E Choonara; Lomas K Tomar; Pradeep Kumar; Charu Tyagi; Lisa C du Toit; Viness Pillay
Journal:  Biomed Res Int       Date:  2015-09-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.